Treatment of type 1 diabetes with teplizumab: clinical and immunological follow-up after 7 years from diagnosis

Diabetologia

Volumn 62, Issue 4, 2019, Pages 655-664

  Perdigoto, Ana Luisa ^a   Preston Hurlburt, Paula ^a   Clark, Pamela ^a   Long, S Alice ^b   Linsley, Peter S ^b   Harris, Kristina M ^c   Gitelman, Steven E ^d   Greenbaum, Carla J ^b   Gottlieb, Peter A ^e   Hagopian, William ^f   Woodwyk, Alyssa ^g   Dziura, James ^a   Herold, Kevan C ^a  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b BENAROYA RESEARCH INSTITUTE   (United States)

^c Biomarker Discovery Research   (United States)

^d UNIVERSITY OF CALIFORNIA   (United States)

^e UNIVERSITY OF COLORADO SCHOOL OF MEDICINE   (United States)

^f PACIFIC NORTHWEST RESEARCH INSTITUTE   (United States)

^g WESTERN MICHIGAN UNIVERSITY   (United States)

Author keywords

Anergy; Anti CD3; C peptide; Exhaustion; T cells; Teplizumab; Type 1 diabetes

Indexed keywords

AUTOANTIBODY; C PEPTIDE; GAMMA INTERFERON; HEMOGLOBIN A1C; INSULIN; INTERLEUKIN 2; PROGRAMMED DEATH 1 RECEPTOR; TEPLIZUMAB; ANTIDIABETIC AGENT; CD3 ANTIGEN; CYTOKINE; MONOCLONAL ANTIBODY;

ARTICLE; CD8+ T LYMPHOCYTE; CHILD; CLINICAL ARTICLE; CONTROLLED STUDY; CYTOKINE RELEASE; CYTOKINE RESPONSE; DISEASE DURATION; FEMALE; FLOW CYTOMETRY; FOLLOW UP; FUNCTION TEST; HUMAN; HYPOGLYCEMIA; IMMUNOTHERAPY; INSULIN DEPENDENT DIABETES MELLITUS; INSULIN TREATMENT; MALE; MIXED MEAL TOLERANCE TEST; MRNA EXPRESSION LEVEL; MULTICENTER STUDY; OPEN STUDY; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SCHOOL CHILD; ADOLESCENT; ADULT; AREA UNDER THE CURVE; AUTOIMMUNITY; BLOOD; CYTOLOGY; DRUG EFFECT; IMMUNOLOGY; METABOLISM; PANCREAS ISLET; RANDOMIZED CONTROLLED TRIAL (TOPIC); REMISSION; TREATMENT OUTCOME; YOUNG ADULT;

ADOLESCENT; ADULT; ANTIBODIES, MONOCLONAL, HUMANIZED; AREA UNDER CURVE; AUTOIMMUNITY; C-PEPTIDE; CD3 COMPLEX; CD8-POSITIVE T-LYMPHOCYTES; CHILD; CYTOKINES; DIABETES MELLITUS, TYPE 1; FEMALE; FOLLOW-UP STUDIES; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN; ISLETS OF LANGERHANS; MALE; RANDOMIZED CONTROLLED TRIALS AS TOPIC; REMISSION INDUCTION; TREATMENT OUTCOME; YOUNG ADULT;

EID: 85058847045     PISSN: 0012186X     EISSN: 14320428     Source Type: Journal    
DOI: 10.1007/s00125-018-4786-9     Document Type: Article

References (18)

1. Herold KC, Vignali DA, Cooke A, Bluestone JA (2013) Type 1 diabetes: translating mechanistic observations into effective clinical outcomes. Nat Rev Immunol 13(4):243–256. 10.1038/nri3422
2. Reed JC, Herold KC (2015) Thinking bedside at the bench: the NOD mouse model of T1DM. Nat Rev Endocrinol 11(5):308–314. 10.1038/nrendo.2014.236
3. Naushad N, Perdigoto AL, Rui J, Herold KC (2017) Have we pushed the needle for treatment of type 1 diabetes? Curr Opin Immunol 49:44–50. 10.1016/j.coi.2017.09.004
4. Pescovitz MD, Greenbaum CJ, Krause-Steinrauf H et al (2009) Rituximab, B-lymphocyte depletion, and preservation of beta-cell function. N Engl J Med 361(22):2143–2152. 10.1056/NEJMoa0904452
5. Pescovitz MD, Greenbaum CJ, Bundy B et al (2014) B-lymphocyte depletion with rituximab and beta-cell function: two-year results. Diabetes Care 37(2):453–459. 10.2337/dc13-0626
6. Rigby MR, Harris KM, Pinckney A et al (2015) Alefacept provides sustained clinical and immunological effects in new-onset type 1 diabetes patients. J Clin Invest 125(8):3285–3296. 10.1172/JCI81722
7. Orban T, Bundy B, Becker DJ et al (2014) Costimulation modulation with abatacept in patients with recent-onset type 1 diabetes: follow-up 1 year after cessation of treatment. Diabetes Care 37(4):1069–1075. 10.2337/dc13-0604
8. Keymeulen B, Walter M, Mathieu C et al (2010) Four-year metabolic outcome of a randomised controlled CD3-antibody trial in recent-onset type 1 diabetic patients depends on their age and baseline residual beta cell mass. Diabetologia 53(4):614–623. 10.1007/s00125-009-1644-9
9. Herold KC, Gitelman SE, Ehlers MR et al (2013) Teplizumab (anti-CD3 mAb) treatment preserves C-peptide responses in patients with new-onset type 1 diabetes in a randomized controlled trial: metabolic and immunologic features at baseline identify a subgroup of responders. Diabetes 62(11):3766–3774. 10.2337/db13-0345
10. Long SA, Thorpe J, DeBerg HA et al (2016) Partial exhaustion of CD8 T cells and clinical response to teplizumab in new-onset type 1 diabetes. Sci Immunol 1(5):eaai7793. 10.1126/sciimmunol.aai7793
11. Tooley JE, Vudattu N, Choi J et al (2016) Changes in T-cell subsets identify responders to FcR-nonbinding anti-CD3 mAb (teplizumab) in patients with type 1 diabetes. Eur J Immunol 46(1):230–241. 10.1002/eji.201545708
12. Long SA, Thorpe J, Herold KC et al (2017) Remodeling T cell compartments during anti-CD3 immunotherapy of type 1 diabetes. Cell Immunol 319:3–9. 10.1016/j.cellimm.2017.07.007
13. Hagopian W, Ferry RJ Jr, Sherry N et al (2013) Teplizumab preserves C-peptide in recent-onset type 1 diabetes: two-year results from the randomized, placebo-controlled Protege trial. Diabetes 62(11):3901–3908. 10.2337/db13-0236
14. Sherry N, Hagopian W, Ludvigsson J et al (2011) Teplizumab for treatment of type 1 diabetes (Protege study): 1-year results from a randomised, placebo-controlled trial. Lancet 378(9790):487–497. 10.1016/S0140-6736(11)60931-8
15. Herold KC, Hagopian W, Auger JA et al (2002) Anti-CD3 monoclonal antibody in new-onset type 1 diabetes mellitus. N Engl J Med 346(22):1692–1698. 10.1056/NEJMoa012864
16. Palmer JP, Fleming GA, Greenbaum CJ et al (2004) C-peptide is the appropriate outcome measure for type 1 diabetes clinical trials to preserve beta-cell function: report of an ADA workshop, 21-22 October 2001. Diabetes 53(1):250–264. 10.2337/diabetes.53.1.250
17. Herold KC, Gitelman SE, Willi SM et al (2013) Teplizumab treatment may improve C-peptide responses in participants with type 1 diabetes after the new-onset period: a randomised controlled trial. Diabetologia 56(2):391–400. 10.1007/s00125-012-2753-4
18. Sherr JL, Ghazi T, Wurtz A, Rink L, Herold KC (2014) Characterization of residual beta cell function in long-standing type 1 diabetes. Diabetes Metab Res Rev 30(2):154–162. 10.1002/dmrr.2478